A Multicenter, Randomized, Double-blind, Active-contrelled, Parallel-group, Phase IV Clinical Trial to Investigate the Effect on Blood Glucose of Evogliptin After Oral Administration in Patiend With Type 2 Diabetes
Latest Information Update: 31 Jul 2021
At a glance
- Drugs Evogliptin (Primary) ; Linagliptin
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- Acronyms EVERGREEN
- Sponsors Dong-A ST
- 22 Jul 2021 Results of a meta-analysis of six randomized controlled trials assessing evogliptin versus placebo and versus other DPP-4 inhibitors conducted following the development of evogliptin, published in the Clinical Therapeutics
- 11 Jun 2019 Primary endpoint (HbA1c) has been met presented at the 79th Annual Scientific Sessions of the American Diabetes Association
- 11 Jun 2019 Results assessing efficacy and safety of Evogliptin compared to linagliptin in patients with type 2 diabetes presented at the 79th Annual Scientific Sessions of the American Diabetes Association